Post di Diatheva srl

📣𝐍𝐞𝐰 𝐞𝐯𝐞𝐧𝐭𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐡𝐨𝐫𝐢𝐳𝐨𝐧 𝐟𝐨𝐫 𝐎𝐥𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐞𝐧𝐭𝐢𝐫𝐞 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐭𝐮𝐢𝐜𝐚𝐥 𝐬𝐞𝐜𝐭𝐨𝐫! 👉Save the date from the June 5th to 7th. You will find us at the 𝟔𝟑° 𝐀𝐅𝐈 𝐬𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 🧑💼👩💼 🔗Stay tuned for more updates in the coming weeks!🔗 #pharmaceuticals #healthcareinnovation #pharmaindustry #industryevents #networkinginpharma #pharmatrends

Some thoughts on the comparison of the final list of drugs selected for negotiation versus the list Sean Dickson and I published in Journal of Managed Care & Specialty Pharmacy: Based on 2020 data (most recent available at the time of our analysis), we guessed: -Eliquis -Jardiance -Xarelto -Januvia -Enbrel -Imbruvica Farxiga, Stelara, Entresto have had major increases in spending in 2020-2022, surpassing some of the other drugs we predicted (Stelara and Entresto more than doubled in gross spending and Farxiga more than tripled). Insulin aspart was always an uncertainty given unclear timing of biosimilar entry. Access to recent data is crucial for predictions, unfortunately, this is only available to CMS and not to the public. I look forward to continue doing research in this area. Stay tuned for more work coming out of us! #IRA #drugnegotiation #pharmaceuticalpolicy

Off-label treatments can be key for #RareDisease patients, but can obfuscate the ground-level view of #PatientJourneys and outcomes. Our analysis with the Foundation For Sarcoidosis Research looked at trends in use of brand name vs biosimilar drugs based on payer type: https://lnkd.in/gMrJnqCe

As the year draws to a close, National CooperativeRx is revisiting our 2023 pharmacy benefit industry predictions and unveiling fresh insights for 2024. Click the blog below to gain valuable perspectives on potential trend drivers, the evolving drug pipeline, industry regulations, and more. #NationalCooperativeRx #PharmacyBenefits #PharmacyTrend

Futura Medical PLC (AIM:FUM, OTC:FAMDF) said it has secured regulatory approval for its fast-acting gel-based #ErectileDysfunction treatment, #MED3000, in Saudi Arabia. The product will be launched and marketed by Labatec Pharma SA as #Eroxon in the fourth quarter. Manufacturing for the launch is complete and will be accompanied by a comprehensive marketing campaign. "Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes," said chief executive James Barder. "This approval comes at a pivotal time for the company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network." Saudi Arabia ranks among the top ten global markets for erectile dysfunction treatments, with 10.45% of its married male population reportedly affected. More at #Proactive #ProactiveInvestors #AIM #OTC #FUM #FAMDF http://ow.ly/wb7v104QGhK

The introduction of new #generics and #biosimilars softens trends but is outpaced by #manufacturer price increases, growing utilization of #brand drugs and costly new products. The complex #pharmacy marketplace continues to evolve as new products are introduced and #treatment paradigms are updated. Mercer US Government's pharmacy team monitors market and pipeline developments to incorporate real-time insights into our analysis. Ryan Ferguson, MPH, Noah Greenberg and Bethany Holderread, PharmD share the projected pharmacy #trend highlights for 2024 and beyond including overall #Medicaid #spending projections, trend drivers and other considerations and #specialty #drug and #genetherapy pipeline. https://bit.ly/3VAD1Ps

The US FDA has Granted Approval to Novartis’ Fabhalta (iptacopan) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) #novartis #fabhalta #iptacopan #paroxysmalnocturnalhemoglobinuria #regulatory #usfda #applypnh #appointpnh #approval #phase3 #pnhpatients #hemoglobinlevels